Saline (0.9%, sterile, for infusion)
DrugSailine as control
NCT Number: NCT07152600
Severe community-acquired pneumonia caused by adenovirus (hereafter referred to as severe adenovirus pneumonia) is one of the common forms of severe community-acquired pneumonia in immunocompetent adults. It predominantly affects young individuals, progresses rapidly, and is associated with a high incidence of respiratory failure and multiple organ dysfunction. At present, there is no effective antiviral therapy available in China, and the reported mortality rate ranges from 41.5% to 80%. How to effectively reduce the mortality of severe adenovirus pneumonia, on the basis of conventional supportive care, is crucial for improving the prognosis of critically ill patients and alleviating the burden on families and society. We are currently conducting an adaptive, randomized, open-label controlled trial aimed at reducing mortality in severe adenovirus pneumonia. The primary objective of this study is to evaluate the efficacy and safety of adjunctive corticosteroid therapy at different dosages, in addition to early standard supportive treatment, in lowering mortality among patients with severe adenovirus pneumonia.
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Phase 3
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
(i) Requirement for endotracheal intubation and mechanical ventilation;
(ii) Septic shock requiring vasopressor therapy after adequate fluid resuscitation.
-Or simultaneously fulfilling three of the minor criteria:
(i) Respiratory rate ≥ 30 breaths/min;
(ii) PaO₂/FiO₂ ≤ 250 mmHg;
(iii) Multilobar infiltrates;
(iv) Altered mental status and/or disorientation;
(v) Blood urea nitrogen ≥ 20 mg/dL (7.12 mmol/L);
(vi) Leukopenia (white blood cell count < 4 × 10⁹/L);
(vii) Thrombocytopenia (platelet count < 100 × 10⁹/L);
(viii) Hypothermia (core temperature < 36 °C);
(ix) Hypotension (systolic blood pressure < 90 mmHg) requiring aggressive fluid resuscitation.
Exclusion criteria
Sailine as control
Methylprednisolone 0.5mg/kg ivgtt qd
Methylprednisolone 1.0mg/kg ivgtt qd
Time frame: 28 days from inclusion
Qingyuan Zhan
Other
An Embedded Adaptive Randomized Controlled Trial of Corticosteroid Therapy for Severe Adenovirus Community-Acquired Pneumonia in Adults
Acronym: CAPSTONE-AD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04285788
Adenoviridae Infections, Adenovirus Infections, Human
View Trial DetailsNCT07726095
Community-Acquired Infections, Community-Acquired Pneumonia
Zhengzhou, Henan, China
View Trial DetailsNCT07697885
Community-Acquired Infections, Community-Acquired Pneumonia
View Trial DetailsNCT07679789
Bacterial Infections, Bacterial Infections and Mycoses
Saint-Denis, France
View Trial Details